Lakewood-Amedex Biotherapeutics Inc. filed an 8-K announcing the completed redemption of all 127,097 outstanding shares of its Series C Convertible Preferred Stock on November 5, 2026, for a total cash payment of $1,270,970.
Key Highlights
- Full redemption completed: All 127,097 shares of Series C Convertible Preferred Stock were redeemed, leaving no preferred shares outstanding.
- Aggregate cash price: The company paid $1,270,970, funded from cash on hand.
- Counterparty: The redemption was executed pursuant to an agreement dated November 2, 2026, with Shakawe Capital LLC.
- No further dilution: According to the filing, no additional shares of common stock will be issuable upon conversion of the Series C Preferred Stock.
- Debt-free preferred structure: Following the redemption, the company reported no shares of preferred stock outstanding and no outstanding indebtedness for borrowed money.
- Restrictions removed: The filing states the redemption eliminates all financing restrictions associated with the Series C Preferred Stock.
Lakewood-Amedex Closes Series C Preferred Redemption With Shakawe Capital
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT), a clinical-stage biotechnology company, disclosed on November 5, 2026, that it had completed the redemption of all remaining outstanding shares of its Series C Convertible Preferred Stock. The transaction was carried out under a redemption agreement dated November 2, 2026, with Shakawe Capital LLC. The company redeemed 127,097 shares at an aggregate cash redemption price of $1,270,970, which the filing states was funded from cash on hand.
According to the filing, following the transaction no shares of Series C Preferred Stock remain outstanding, and no additional shares of the company's common stock will be issuable upon conversion of that class of stock. The company further reported that it now has no shares of preferred stock of any class outstanding and carries no outstanding indebtedness for borrowed money. The filing also states that the redemption eliminates all restrictions previously associated with the Series C Preferred Stock.
Chief Executive Officer Kelvin Cooper, Ph.D., was quoted in the filing stating that completing the redemption "simplifies our capital structure and eliminates the potential for further dilution from conversion of the Series C Preferred Stock," and that it "removes the financing restrictions associated with that instrument, giving us greater financial flexibility as we continue to advance our development programs." The filing notes that it contains forward-looking statements subject to risks and uncertainties, including the possibility that anticipated benefits of the redemption may not be realized and that the use of cash to fund the redemption may reduce the company's liquidity and cash runway.
What Was Disclosed
The company disclosed the full redemption of 127,097 Series C Convertible Preferred Stock shares for $1,270,970 in cash under a November 2, 2026, agreement with Shakawe Capital LLC, leaving the company with no preferred stock outstanding and no indebtedness for borrowed money.



Please wait processing your request...